President Donald Trump isn’t just talking about making America great again — he’s making our pharmaceutical and biotech industries the envy of the world. Why? Because it’s not just about jobs (though there are a lot of them coming), it’s about national security and putting America back in charge of its own medicine cabinet.
Just ask Gilead Sciences, which just threw down a jaw-dropping $11 billion to beef up its U.S. operations. That’s not pocket change — that’s serious commitment. And Gilead isn’t alone.
Johnson & Johnson, straight out of New Jersey, announced a colossal $55 billion investment across manufacturing, research and development, and technology. That’s called doubling down on America.
Meanwhile, Swiss giant Roche clearly got the memo and is throwing in a cool $50 billion for its U.S.-based manufacturing and R&D. Apparently, even the Swiss want in on Trump’s vision.
Bristol Myers Squibb — also Jersey-born — pledged $40 billion into their research, development, and manufacturing. They’re not playing around either.
Eli Lilly from Indiana decided to more than double their domestic manufacturing capacity with a massive $27 billion investment. That’s not just a win for Indiana — that’s a win for American medicine, period.
Novartis, another Swiss firm, is investing $23 billion to build or expand ten manufacturing sites across the U.S. Seems like even overseas companies are more patriotic than some of our own politicians.
Then there’s AbbVie, hailing from Illinois, promising $10 billion over the next decade to support volume growth and roll out four new manufacturing plants. Yes, four.
Merck & Co. jumped in with a $9 billion total investment plan, on top of a brand-new $1 billion manufacturing site in North Carolina — and just to flex even harder, they’re also building a shiny new biologics plant in Delaware.
Even Merck Animal Health is getting in on the action with an $895 million investment in Kansas. Who said only humans get the perks?
Regeneron, based in New York, sealed a $3 billion deal with FUJIFILM Diosynth Biotechnologies to crank out drugs in North Carolina. Biotech boom, anyone?
California’s Amgen isn’t sleeping either, putting $900 million into its Ohio plant. That’s West Coast money working for the Midwest.
And Abbott Laboratories, repping Illinois again, is dropping $500 million between its home state and Texas. That’s what we call red-state energy.
President Trump’s America First approach isn’t just working — it’s lighting a fire under the entire pharmaceutical industry. Billions are pouring in, manufacturing is booming, and for once, America is back in charge of its own health. That’s how you win.